MedPath

Anti-GPC3 CAR T for Treating Patients With Advanced HCC

Phase 1
Completed
Conditions
Hepatocellular Carcinoma
Registration Number
NCT02395250
Lead Sponsor
RenJi Hospital
Brief Summary

The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize glypican-3 (GPC3) is safe and effective for patients with relapsed or refractory hepatocellular carcinoma (HCC).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
13
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Adverse events attributed to the administration of the anti-GPC3 CAR T cells2 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Shanghai Cancer Institute

🇨🇳

Xuhui, Shanghai, China

Shanghai Cancer Institute
🇨🇳Xuhui, Shanghai, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.